Ketamine For Antidepressant-Resistant PTSD
This randomized clinical trial proposes to consent 240 Veterans and active-duty military personnel with antidepressant-resistant posttraumatic stress disorder (PTSD) at two sites (VA Connecticut Healthcare System, West Haven Campus and the San Antonio Military Medical Center; SAMMC) to test the safety and efficacy of repeated doses of intravenously administered ketamine as compared to placebo, in reducing symptoms of PTSD. At SAMMC, up to 120 active duty military personnel will be consented to randomize 99 and obtain complete data on 80 for analysis. After consent and screening, eligible individuals will be randomized to one of three treatment groups to receive placebo, ketamine 0.2 mg/kg, or ketamine 0.5 mg/kg.